ES2084827T3 - Composiciones de vacuna mejoradas. - Google Patents

Composiciones de vacuna mejoradas.

Info

Publication number
ES2084827T3
ES2084827T3 ES91915418T ES91915418T ES2084827T3 ES 2084827 T3 ES2084827 T3 ES 2084827T3 ES 91915418 T ES91915418 T ES 91915418T ES 91915418 T ES91915418 T ES 91915418T ES 2084827 T3 ES2084827 T3 ES 2084827T3
Authority
ES
Spain
Prior art keywords
vaccine compositions
improved vaccine
compositions
improved
immunogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91915418T
Other languages
English (en)
Inventor
Christopher L Penney
Francis Michon
Harold J Jennings
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North American Vaccine Inc
Original Assignee
North American Vaccine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North American Vaccine Inc filed Critical North American Vaccine Inc
Application granted granted Critical
Publication of ES2084827T3 publication Critical patent/ES2084827T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

COMPOSICIONES MEJORADAS PARA VACUNAS QUE CONTIENEN UN COMPUESTO ALQUILO DE CADENA LARGA COMO AGENTE INMUNOAUXILIAR JUNTO CON UN CONJUGADO DE PROTEINAS DE POLISACARIDOS BACTERIANAS. LAS COMPOSICIONES DE LA INVENCION SON UTILES PARA ACTIVAR EL SISTEMA INMUNE PARA CONFERIR INMUNIDAD A UN HUESPED CONTRA EL INMUNOGEN DE UNA MANERA PROFILACTICA.
ES91915418T 1990-09-17 1991-09-12 Composiciones de vacuna mejoradas. Expired - Lifetime ES2084827T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58337290A 1990-09-17 1990-09-17

Publications (1)

Publication Number Publication Date
ES2084827T3 true ES2084827T3 (es) 1996-05-16

Family

ID=24332852

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91915418T Expired - Lifetime ES2084827T3 (es) 1990-09-17 1991-09-12 Composiciones de vacuna mejoradas.

Country Status (28)

Country Link
US (1) US5773007A (es)
EP (1) EP0549617B1 (es)
JP (1) JPH06500772A (es)
CN (1) CN1060408A (es)
AT (1) ATE135918T1 (es)
AU (1) AU8441991A (es)
BR (1) BR9106853A (es)
CA (1) CA2090673A1 (es)
CS (1) CS283991A3 (es)
CZ (1) CZ42993A3 (es)
DE (1) DE69118389T2 (es)
DK (1) DK0549617T3 (es)
ES (1) ES2084827T3 (es)
FI (1) FI931169L (es)
GR (1) GR3020117T3 (es)
HR (1) HRP920874A2 (es)
HU (1) HUT64237A (es)
IE (1) IE913261A1 (es)
IL (1) IL99403A0 (es)
IS (1) IS3753A7 (es)
MX (1) MX9101077A (es)
NO (1) NO930938L (es)
NZ (1) NZ239643A (es)
OA (1) OA09776A (es)
SK (1) SK18693A3 (es)
WO (1) WO1992004915A1 (es)
YU (1) YU153291A (es)
ZA (1) ZA917356B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1008977A5 (fr) * 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
US5695768A (en) 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
US5866132A (en) * 1995-06-07 1999-02-02 Alberta Research Council Immunogenic oligosaccharide compositions
US6007819A (en) * 1995-10-17 1999-12-28 Dovetail Technologies, Inc. Methods of inducing immunity using low molecular weight immune stimulants
PL328096A1 (en) * 1996-02-01 1999-01-04 North American Vaccine Expression of external membrane (mb3) protein of neisseria meningitidis of b group in yeasts and vaccines
US6299881B1 (en) * 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
CA2316975C (en) 1997-12-23 2009-03-24 North American Vaccine, Inc. Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US6858211B1 (en) * 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
CA2714833A1 (en) * 1998-07-20 2000-02-03 Edward Konadu (Deceased) Vaccines against escherichia coli o157 infection
US6824997B1 (en) 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US20080096236A1 (en) * 1998-08-25 2008-04-24 Binax, Inc. Method for Detecting the Presence of Target Bacteria or a Target Component Carbohydrate Antigen Thereof
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
JP2002539273A (ja) * 1999-03-19 2002-11-19 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PT2332581E (pt) * 2001-01-23 2015-10-16 Sanofi Pasteur Inc Vacina meningocócica tri- ou tetravalente de conjugados de polissacárido e crm-197
US20030035806A1 (en) * 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
US7534442B2 (en) * 2001-08-21 2009-05-19 The Brigham And Women's Hospital, Inc. Immunogenic compositions comprising covalently bound polysaccharides, antigen, and bacterial toxoid
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
MXPA05008156A (es) * 2003-02-01 2005-09-30 Neuralab Ltd Inmunizacion activa para generar anticuerpos para beta-a soluble.
CA2844154C (en) * 2003-08-06 2016-12-20 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
EP2007427A4 (en) * 2006-04-11 2012-04-04 Yeda Res & Dev IMPROVED VACCINES WITH MULTIMETER HSP60 PEPTIDE SUPPORTS
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
SI2182983T1 (sl) * 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
NZ612315A (en) * 2009-04-14 2014-10-31 Novartis Ag Compositions for immunising against staphylococcus aureus
US8003112B2 (en) * 2009-04-16 2011-08-23 Howard University Meningococcal and pneumococcal conjugate vaccine and method of using same
CN102481352A (zh) 2009-06-22 2012-05-30 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
SA114350400B1 (ar) 2009-06-22 2016-05-26 ويث ال ال سي تركيبات وطرق لتحضير تركيبات مولدة للمناعة لمقترن بولي سكاريد كبسولي للنمط المصلي 5 و 8 من المكورات العنقودية الذهبية
CN104582723A (zh) * 2012-08-31 2015-04-29 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
CN102839159B (zh) * 2012-09-07 2014-03-19 江苏康淮生物科技有限公司 一种CoxA16病毒株和人用CoxA16灭活疫苗
CN106606775A (zh) * 2015-10-27 2017-05-03 格里菲斯大学 脂质体a群链球菌疫苗
TWI770044B (zh) * 2016-08-05 2022-07-11 南韓商Ｓｋ生物科技股份有限公司 多價肺炎球菌多醣-蛋白質共軛物組成物(一)
BR112020004509A8 (pt) 2017-09-07 2023-01-31 Merck Sharp & Dohme Conjugado polissacarídeo-proteína carreadora, composição imunogênica compreendendo o mesmo e uso do referido conjugado
KR20230008923A (ko) 2018-02-05 2023-01-16 사노피 파스퇴르 인코포레이티드 다가 폐렴구균성 다당류-단백질 접합체 조성물
EP3782642A4 (en) 2018-04-18 2022-04-13 SK Bioscience Co., Ltd. CAPSULE POLYSACCHARIDES FROM STREPTOCOCCUS PNEUMONIAE AND CONJUGATES THEREOF
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1138773A (en) * 1979-04-18 1983-01-04 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US4258029A (en) * 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US5019383A (en) * 1981-01-09 1991-05-28 New York Blood Center, Inc. Fatty acid carriers for synthetic peptides
EP0064366A1 (en) * 1981-04-29 1982-11-10 Beecham Group Plc Pharmaceutical compositions
US4663160A (en) * 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4639371A (en) * 1984-10-02 1987-01-27 New York Blood Center, Inc. Hepatitis B antigenic compositions and vaccines against hepatitis B derived therefrom
CA1267087A (en) * 1985-02-14 1990-03-27 Nicolaas Visser Synthetic immunogen
US4863735A (en) * 1985-02-19 1989-09-05 Massachusetts Institute Of Technology Biodegradable polymeric drug delivery system with adjuvant activity
FR2581877B1 (fr) * 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
DK163176C (da) * 1985-09-27 1992-06-22 Schweiz Serum & Impfinst Ugiftig konjugatvaccine mod infektioner af pseudomonas aeruginosa- og escherichia coli- bakterier, fremgangsmaade til fremstilling heraf og anvendelse af vaccinen
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
EP0273512B1 (en) * 1986-12-19 1991-02-27 Duphar International Research B.V Stabilised adjuvant suspension comprising dimethyl dioctadecyl ammonium bromide
NZ223009A (en) * 1986-12-31 1990-06-26 Nl Rivm Of Thoven Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens
EP0289110A3 (en) * 1987-02-02 1990-01-24 Swiss Serum and Vaccine Institute Berne Conjugate malaria vaccine
GB8807860D0 (en) * 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
NZ230424A (en) * 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen
EP0449958B9 (en) * 1988-12-19 2003-05-28 American Cyanamid Company Meningococcal class 1 outer-membrane protein vaccine

Also Published As

Publication number Publication date
NZ239643A (en) 1996-05-28
ZA917356B (en) 1992-09-30
YU153291A (sh) 1994-06-24
HRP920874A2 (en) 1996-04-30
HUT64237A (en) 1993-12-28
FI931169A7 (fi) 1993-04-22
CN1060408A (zh) 1992-04-22
FI931169A0 (fi) 1993-03-16
AU8441991A (en) 1992-04-15
JPH06500772A (ja) 1994-01-27
DE69118389D1 (de) 1996-05-02
CZ42993A3 (en) 1994-04-13
IL99403A0 (en) 1992-08-18
NO930938D0 (no) 1993-03-16
IE913261A1 (en) 1992-02-25
SK18693A3 (en) 1993-08-11
CS283991A3 (en) 1992-04-15
EP0549617A1 (en) 1993-07-07
WO1992004915A1 (en) 1992-04-02
US5773007A (en) 1998-06-30
GR3020117T3 (en) 1996-08-31
EP0549617B1 (en) 1996-03-27
HU9300746D0 (en) 1993-06-28
OA09776A (en) 1993-11-30
NO930938L (no) 1993-03-16
CA2090673A1 (en) 1992-03-18
FI931169L (fi) 1993-04-22
DE69118389T2 (de) 1996-08-29
DK0549617T3 (da) 1996-04-22
MX9101077A (es) 1992-05-04
IS3753A7 (is) 1992-03-18
BR9106853A (pt) 1993-08-17
ATE135918T1 (de) 1996-04-15

Similar Documents

Publication Publication Date Title
MX9101077A (es) Composicion para vacuna que comprende un conjugado de proteina-polisacarido bacteriano y un adyuvante de alquilo de cadena larga
ES2192582T3 (es) Composicion de vaccineo, conteniendo quitina, parcialmente deacetilado.
BR9912410A (pt) Vacina para imunização de aves, e, processos para imunizar uma ave e para preparar uma vacina para imunizar uma ave
ES2121820T3 (es) Vacuna de conjugados de polisacaridos de neumococos.
ES2140076T3 (es) Vacunas que contienen una saponina y un esterol.
ES2154263T3 (es) Vacuna a base de conjugados de o-polisacarido-proteina de escherichia coli.
ES2098029T3 (es) Vacunas de hepatitis que contienen monofosforil lipido a 3-o-desacilado.
AR023535A1 (es) Nuevas composiciones.
ES2124701T3 (es) Composiciones de vacunas.
AR114627A1 (es) Composición inmunogénica
HUP9701586A2 (hu) Javított inaktivált vakcinák
ES2058176T3 (es) Un procedimiento para preparar un derivado peptidico.
ES2054732T3 (es) Un procedimiento para preparar un derivado peptidico.
ES2043901T3 (es) Adyuvante para la terapia inmunologica del cancer.
ES2136064T3 (es) Vacunas de toxoide de pasteurella multocida.
ES2166763T3 (es) Inmunizacion parenteral contra rotavirus.
MX9301736A (es) Vacuna de bacterina-toxoide de pasteurella haemolytica tipo a-1.
PL341541A1 (en) Isolated strains of staphyloccoccus aureus and vaccines prepared of them
ES2059605T3 (es) Vacuna toxoide de la tosferina.
EP0339040A4 (en) Swine dysentery vaccine.
ES2102836T3 (es) El empleo de vacunas antihelminticas en el control de la enfermedad parasitaria asociada con la perdida de la inmunidad natural.
DE69130953D1 (de) Immunverstärkung von impfstoffen, besonders von impfstoffen gegen schweinepleuropneumonie
MX9704824A (es) Adyuvantes para vacunas.
RU93005000A (ru) Композиция вакцин, способ ее получения, способ исключения иммунной реакции
SU1713152A1 (ru) Адъювант для ящурной вакцины

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 549617

Country of ref document: ES